OUR ENJAYMO WEBSITES WILL BE BACK ONLINE SOON

We are pleased to share that, as of November 29, 2024, Recordati Rare Diseases has officially completed the acquisition of the global rights to Enjaymo^® from Sanofi, following all necessary regulatory approvals.

This is an important step forward for both patients and healthcare providers, as it strengthens our commitment to bringing innovative treatments to those who need them most. The full press release can be found here.

This should not impact your ability to access ENJAYMO.

GET MORE INFORMATION

For our patients and our healthcare professionals, our focus remains on serving you.

If you have any questions, call ENJAYMO Patient Solutions at:

1-833-223-2428

For healthcare professionals:

If you have any medical information inquiries, please call:

1-888-575-8344 or 1-908-787-8050
(M-F 8 AM-6 PM CST)

medinfo@recordatirarediseases.com

OUR ENJAYMO WEBSITES WILL BE BACK ONLINE SOON

We are pleased to share that, as of November 29, 2024, Recordati Rare Diseases has officially completed the acquisition of the global rights to Enjaymo® from Sanofi, following all necessary regulatory approvals.

We are pleased to share that, as of November 29, 2024, Recordati Rare Diseases has officially completed the acquisition of the global rights to Enjaymo^® from Sanofi, following all necessary regulatory approvals.